New drug shows promise in destroying amyloidosis cells
NCT ID NCT07524634
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This study tests an experimental drug called elranatamab in people newly diagnosed with AL amyloidosis who have not yet had treatment. The drug helps the body's immune cells find and destroy the abnormal cells causing the disease. Researchers want to see if it can produce deep remissions and improve organ function, and they are comparing two different dosing schedules. About 64 participants will receive injections over 6 months and be followed for up to 2 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOID LIGHT-CHAIN AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute
Cleveland, Ohio, 44195, United States
-
Mayo Clinic
Rochester, Minnesota, 55902, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.